Peter Rost further stirs the pot on Pfizer promoting the off-label use of Mirapex for restless leg syndrome (RLS). The thing is, Mirapex really is recommended as first-line treatment for RLS (via UptoDate):
Begin with pramipexole [Mirapex] (0.125 mg) or ropinirole (1.0 mg) approximately one hour before the usual time of symptom onset; the dose is titrated upward according to response. These drugs are effective and well tolerated by most patients
Off-topic, I like how the Pfizer drug rep described Neurontin:
Neurontin – Christ! Pick a disease. Any disease! Although, much of this off-label use was physician-driven. I recall one of my Neurologists describing Neurontin as the’Swiss Army Knife’ of pharmaceuticals.






![Medical brain drain leaves vulnerable communities without life-saving care [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-1-190x100.jpg)
![Regulatory red tape threatens survival of rare disease patients [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-4-190x100.jpg)
![Catching type 1 diabetes before it becomes life-threatening [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-2-190x100.jpg)



![Sustainable legislative reform outweighs temporary discount programs [PODCAST]](https://kevinmd.com/wp-content/uploads/The-Podcast-by-KevinMD-WideScreen-3000-px-4-190x100.jpg)